Vertex Closes $10 Billion Crinetics Acquisition
Vertex Pharmaceuticals says the acquisition adds a fourth commercial pillar in rare endocrine diseases. Crinetics' Palsonify generated $10 million in September sales and has captured more than 40% brand share.
Vertex Pharmaceuticals closes its $10.0 billion acquisition of Crinetics Pharmaceuticals, adding a fourth commercial pillar in rare endocrine diseases. The deal brings Palsonify, an oral acromegaly treatment that generated $10 million in Sept. sales. Palsonify has captured more than 40% brand share…